Loading stock data…
$2.90-0.09 (-3.01%)
Insight Molecular Diagnostics Inc.
Insight Molecular Diagnostics Inc. in the Healthcare sector is trading at $2.90 with a market capitalization of $110M. Wall Street consensus targets $8.25 (4 analysts), implying a +184.5% move over the next 12 months. The stock is currently near its 52-week low of $2.42, remaining 41.9% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $239,000↑ | $32,000↓ | $1.14M↑ | $260,000↓ | $518,000 |
| Gross Profit | $157,000↑ | $15,000↓ | $496,000↑ | $139,000↓ | $338,000 |
| Operating Income | -$9.09M↑ | -$10.33M↓ | -$9.95M↓ | -$7.67M↓ | -$7.04M |
| Net Income | -$11.26M↓ | -$4.29M↑ | -$22.95M↓ | -$10.85M↓ | -$9.74M |
Insight Molecular Diagnostics Inc. operates as a precision diagnostics company in the United States and internationally. The company develops and commercializes laboratory developed tests, kitted research use only tests, and kitted clinical tests. It...